A Continuation Study of ABT-874 in Subjects with Psoriasis
Research type
Research Study
Full title
A Phase 3, Multi-centre, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study with ABT-874
IRAS ID
12121
Sponsor organisation
Abbott GmbH & Co.KG
Eudract number
2007-005955-40
ISRCTN Number
NA
Clinicaltrials.gov Identifier
Research summary
The purpose of this study is to examine the long term safety, efficacy and tolerability of ABT-874 in patients with moderate to severe chronic plaque psoriasis. Patients who have previously taken part in the Study M10-255 in the UK and have either completed it or lost response to the treatment while in the M10-255 study could potentially take part in this trial.ABT-874 is a protein which is similar to proteins in the body which help fight disease (called an antibody). ABT-874 may help to regulate 2 proteins called IL-12 and IL-23 which may exist at higher levels in people who have psoriasis and may be a reason why people get psoriasis.The study will be conducted at 2 hospitals in the UK and in other hospitals in Europe and North America. The study could potentially last just over 3 years for each patient. Patients will have an injection of ABT-874 every 4 weeks and will have regular visits at hospital as an outpatient every 12 weeks when they will be checked to see how they are doing by having blood tests, physical exams, and by answering questions about how they doing.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
09/H1002/6
Date of REC Opinion
25 Mar 2009
REC opinion
Further Information Favourable Opinion